"Vigabatrin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID. (From Martindale The Extra Pharmacopoeia, 31st ed)
| Descriptor ID |
D020888
|
| MeSH Number(s) |
D02.241.081.114.500.350.900 D12.125.190.350.900
|
| Concept/Terms |
Vigabatrin- Vigabatrin
- gamma-Vinyl-GABA
- gamma Vinyl GABA
- gamma-Vinyl-gamma-Aminobutyric Acid
- Acid, gamma-Vinyl-gamma-Aminobutyric
- gamma Vinyl gamma Aminobutyric Acid
|
Below are MeSH descriptors whose meaning is more general than "Vigabatrin".
Below are MeSH descriptors whose meaning is more specific than "Vigabatrin".
This graph shows the total number of publications written about "Vigabatrin" by people in this website by year, and whether "Vigabatrin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 4 | 0 | 4 |
| 2012 | 1 | 1 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vigabatrin" by people in Profiles.
-
Fosi T, Werner K, Boyd SG, De Haan M, Scott RC, Neville BG. Auditory processing following infantile spasms: An event-related potential study. Epilepsia. 2017 05; 58(5):872-881.
-
Sergott RC, Johnson CA, Laxer KD, Wechsler RT, Cherny K, Whittle J, Feng G, Lee D, Isojarvi J. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures. Epilepsia. 2016 Oct; 57(10):1634-1642.
-
Pellock JM, Faught E, Foroozan R, Sergott RC, Shields WD, Ziemann A, Lee D, Dribinsky Y, Torri S, Othman F, Isojarvi J. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. Epilepsy Behav. 2016 07; 60:174-180.
-
Krauss G, Faught E, Foroozan R, Pellock JM, Sergott RC, Shields WD, Ziemann A, Dribinsky Y, Lee D, Torri S, Othman F, Isojarvi J. Sabril? registry 5-year results: Characteristics of adult patients treated with vigabatrin. Epilepsy Behav. 2016 Mar; 56:15-9.
-
Vendrame M, Guilhoto LM, Loddenkemper T, Gregas M, Bourgeois BF, Kothare SV. Outcomes of epileptic spasms in patients aged less than 3 years: single-center United States experience. Pediatr Neurol. 2012 May; 46(5):276-80.
-
Fecarotta C, Sergott RC. Vigabatrin-associated visual field loss. Int Ophthalmol Clin. 2012; 52(3):87-94, xii.
-
Pellock JM, Faught E, Sergott RC, Shields WD, Burkhart GA, Krauss GL, Foroozan R, Wesche DL, Weinberg MA. Registry initiated to characterize vision loss associated with vigabatrin therapy. Epilepsy Behav. 2011 Dec; 22(4):710-7.
-
Mohamed BP, Scott RC, Desai N, Gutta P, Patil S. Seizure outcome in infantile spasms--a retrospective study. Epilepsia. 2011 Apr; 52(4):746-52.
-
Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand Suppl. 2011; (192):57-71.
-
Sergott RC, Westall CA. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Acta Neurol Scand Suppl. 2011; (192):48-56.